Topical Finasteride: What the Trial and the FDA Alert Both Say

Does topical finasteride work, and is it safer than the pill?

It works. In its phase 3 trial, topical finasteride raised hair count roughly three times more than placebo over 24 weeks and matched oral finasteride numerically. Safer is the contested half. The same trial measured a 34.5% fall in serum DHT on the topical against 55.6% on the pill, which is systemic exposure by definition, and the FDA states that absorption through the skin into the bloodstream is expected. No topical finasteride is FDA approved.

The pitch for topical finasteride is that you get the results of the pill without the risk of the pill. It is a good pitch, it sells a large number of subscriptions, and the trial data behind the first half of it is genuinely decent.

The second half is where this post spends its time. Three bodies of evidence describe the safety of this drug and they do not agree: a real-world dataset of 638,629 men reporting almost no problems, an FDA alert built on 32 reports describing exactly the problems the drug was supposed to avoid, and a European regulator that reviewed the licensed spray and found no signal at all. None of them is lying. Working out what each one can and cannot measure is the whole subject.

Table of contents

• What topical finasteride is, and where it is legal
• What the phase 3 trial actually found
• Topical finasteride is systemic finasteride, just less of it
• What the FDA alert says
• The 638,629-patient study, and who ran it
• Why the two datasets disagree
• What the EU regulator found when it looked at the spray
• What oral finasteride's own numbers look like
• Compounded means the formula is not standardised
• The risk that lands on somebody else
• What to ask before starting

What topical finasteride is, and where it is legal

Topical finasteride is the same 5-alpha reductase inhibitor found in Propecia, formulated as a scalp spray, solution or gel rather than a tablet. The reasoning is that pattern hair loss is driven by DHT acting on follicles in the scalp, so putting the drug where the follicles are should suppress DHT locally while leaving the rest of the body alone.

Its legal status splits sharply by country. In the United States there is no FDA-approved topical formulation of finasteride, and the agency states this plainly: the only approved finasteride products are the oral tablets Proscar, approved in June 1992, and Propecia, approved in December 1997. Everything sold as topical finasteride in the US is a compounded preparation, usually dispensed through a telehealth platform, frequently combined with minoxidil in the same bottle.

Europe is different, and the difference is not a technicality. A licensed 0.25% scalp spray has been approved in several EU member states since 2021, and the European Medicines Agency treats it as an established product: its 2025 safety review states plainly that "finasteride 1 mg tablets and finasteride skin spray are used to treat early androgenetic alopecia" (EMA/142716/2025). A separate spray cleared phase 3 in China. So the drug is approvable, and in several markets it has been approved. The US is not one of them.

That distinction matters more than it sounds. An approved product has a fixed formula, a regulator-reviewed label listing its side effects, and a manufacturer accountable for both. A compounded product has none of those things, which is the thread running through the rest of this post.

What the phase 3 trial actually found

The efficacy evidence is real and it is reasonably good. The pivotal trial randomised 458 men with androgenetic alopecia across 45 European sites in a double-blind, double-dummy design, running topical finasteride against placebo and against oral finasteride 1 mg for 24 weeks (Piraccini et al, J Eur Acad Dermatol Venereol 2022).

Arm	Change in target area hair count at week 24
Topical finasteride	+20.2 hairs
Placebo	+6.7 hairs
Oral finasteride 1 mg	Numerically similar to topical

The gap against placebo was significant at P < 0.001, and topical also beat placebo at week 12 and on investigator-assessed hair growth at week 24. A review putting the two side by side gives the oral figure as +21.1 hairs against the topical's +20.2, close enough that no one should read a winner into the difference (Gupta and Talukder, J Cosmet Dermatol 2022).

A second phase 3 trial in 270 Chinese men, randomised 2:1 against placebo for 24 weeks, confirmed the direction: significantly better hair count at week 24, though at week 12 the difference was only numerical (P = 0.0688) (Zhou et al, Chin Med J 2026). That trial was funded by the company developing the product, as was the European one, whose author list includes Almirall employees.

Two limits are worth keeping in view. Both trials ran 24 weeks, which is long enough to measure hair count and short enough to miss most of what people worry about. And the "three-fold increase" that appears in the marketing is the comparison against placebo, not against the pill.

Topical finasteride is systemic finasteride, just less of it

The trial that is used to argue topical finasteride avoids systemic effects is the same trial that measured its systemic effect. This is the single most important fact on the subject and it sits in the abstract of the paper everyone cites.

Piraccini's team measured plasma finasteride, testosterone and DHT. Maximum plasma finasteride concentrations were more than 100 times lower on topical than oral, which is a genuinely large reduction in drug exposure. Serum DHT, which is the thing that actually mediates both the hair effect and the sexual side effects, fell by 34.5% on topical against 55.6% on oral.

Put differently: the topical produced roughly three fifths of the pill's whole-body DHT suppression. Not none of it. The authors' own conclusion is carefully worded, saying there is "less likelihood" of systemic sexual adverse reactions, which is a statement about probability rather than a claim of absence.

One other finding complicates it further. An open-label pharmacodynamic study cited in the 2022 review found that seven days of twice-daily 0.25% topical finasteride and once-daily oral finasteride 1 mg produced similar inhibition of plasma DHT. That is a small, short, open-label study and it should not outweigh the phase 3 measurement, but it points the same direction: the drug crosses the skin and reaches the blood.

The FDA reaches the same conclusion in one sentence: absorption of finasteride through the skin into the bloodstream is expected. Where the numbers behind a claim come from, and how much weight each study design can carry, is set out on our methodology page.

What the FDA alert says

On 22 April 2025 the FDA issued a compounding risk alert on topical finasteride, and its contents are not what the product's marketing suggests. The agency had received 32 reports of adverse events associated with compounded topical finasteride through its Adverse Event Reporting System between 2019 and 2024 (FDA, compounded topical finasteride alert).

The reported events were, in the FDA's words, consistent with those reported for approved oral finasteride: erectile dysfunction, anxiety, suicidal ideation, brain fog, depression, fatigue, insomnia, decreased libido and testicular pain. Local reactions were listed separately: irritation, erythema, dryness and scaling, stinging and burning.

Three details in the alert deserve to be read directly rather than summarised. Most of the reports state the adverse events continued to persist after the product was discontinued. Some consumers said they had not been aware that any adverse events were possible. And other patients reported being told by their prescribers that there was no risk of any adverse event because the product was topical.

That last line is the reason this alert exists. The FDA is not primarily warning that the drug is dangerous. It is warning that people are being told a topical route removes a risk that the agency's own reading of the pharmacology says it reduces rather than removes.

Thirty-two reports is a small number and it carries the limits every spontaneous reporting system carries. Nobody knows how many people used the product, so no incidence rate can be calculated from it, and a report is an allegation of association rather than proof of causation. What it establishes is that the events occur, which is different from establishing how often.

The 638,629-patient study, and who ran it

The largest dataset on topical finasteride tolerability reports almost no problems at all, and reading it properly requires knowing how it was collected. Published in January 2026, it covers 638,629 men prescribed a compounded topical finasteride and minoxidil product through the Hims & Hers telehealth platform between April 2021 and April 2025 (Yu et al, JMIR Dermatol 2026).

Measure	Number	Share
Prescribed the product	638,629	100%
Completed the day-130 check-in	151,352	23.7% of those prescribed
Satisfied with treatment	121,615	80.4% of responders
Reported a side effect	4,034	2.7% of responders
Messaged care team about a reaction	230	0.04% of those prescribed

The paper reports that no patient reported seeking a higher level of care or discontinued treatment because of a side effect. The authors disclose that four of them are full-time employees of Hims & Hers and two serve as advisors to the company, and state that the company had no role in study design, data collection, analysis or the decision to publish. They also name the study's central limitations themselves: it is retrospective and has no control group, so it cannot support causal conclusions.

Their disclosure is complete and the study is not hidden or dishonest. It is a description of what people told a company about a product they were buying from that company, which is a real measurement of something. The question is what.

Why the two datasets disagree

The gap between 32 harrowing reports and a 2.7% side effect rate is mostly explained by who gets counted, and the arithmetic is worth doing.

The 2.7% figure is a share of responders, not of patients. Of the 638,629 men prescribed the product, 486,000 or so never completed the check-in, a non-response rate of 76.3%. Measured against everyone prescribed, the 4,034 reports work out at 0.63%. Neither number is wrong, and they differ by a factor of four depending only on the denominator you pick.

Non-response is not random here. A man who stopped the product in month two because it gave him brain fog is not a likely candidate to fill in a satisfaction survey on day 130 from the company that sold it to him. He has already left, and a check-in sent to active patients systematically undercounts exactly the people whose experience the FDA reports describe. That is not a flaw the authors hid; it is what "retrospective, no control group" means in practice.

The finding that no patient discontinued because of a side effect should be read in the same light. Among men still engaged enough to answer a check-in at day 130, discontinuation for side effects was not reported. It is a statement about who responded, not a finding that nobody quit.

Neither dataset gives an incidence rate, which is the number people actually want. For that you need a randomised trial with a placebo arm, long enough follow-up and enough participants to detect events at the frequency the oral label reports. The 24-week phase 3 trials found no meaningful difference in adverse events between topical finasteride and placebo, which is reassuring, and were not powered or long enough to settle the question. The same evidence-tier problem shows up across this niche, and we take the same approach to it in minoxidil side effects.

What the EU regulator found when it looked at the spray

European regulators reviewed this drug class in 2025 and reached a different conclusion about the spray than the FDA reached about the compounded version, which is the best evidence available that the distinction between the two is real rather than bureaucratic.

The EMA's safety committee ran an EU-wide review and confirmed suicidal ideation as a side effect of finasteride 1 mg and 5 mg tablets, at a frequency it classed as unknown because the data cannot support an estimate. Most cases were in men taking the 1 mg tablet for hair loss. The review identified 325 relevant cases of suicidal ideation in EudraVigilance, 313 for finasteride and 13 for dutasteride, against an estimated exposure of around 270 million patient years for finasteride.

That denominator is the thing the FDA's 32 reports do not have, and it is why the EMA could reach a conclusion the FDA alert does not attempt. It also means the confirmed risk sits at an unknown but evidently low frequency rather than at zero.

On the spray specifically, the finding was negative. In the agency's words: "The review found no evidence linking suicidal ideation to finasteride skin sprays and no new information is being included in the product information for these sprays."

Read the two regulators together and the split is not Europe against America. It is licensed against compounded. The EMA assessed a fixed-formula 0.25% spray with a known dose and a reviewed label. The FDA received reports about products compounded at whatever concentration a pharmacy chose, often mixed with minoxidil, dispensed with no label listing any of it. Those are different exposures, and the two conclusions may be measuring precisely that difference.

None of which makes the spray inert. The 34.5% fall in serum DHT was measured in the trial that supported the European approval, and the EMA's finding is an absence of evidence for one specific harm in one specific formulation, not a clean bill of health for the drug.

What oral finasteride's own numbers look like

Comparing topical against the pill requires knowing what the pill's numbers are, and they are lower than the internet's reputation for them suggests. The Propecia label reports a 12-month controlled trial in 1,879 men.

Adverse event	Finasteride 1 mg (n=945)	Placebo (n=934)
Decreased libido	1.8%	1.3%
Erectile dysfunction	1.3%	0.7%
Decreased volume of ejaculate	0.8%	0.4%
Discontinued for sexual adverse events	1.2%	0.9%

Those are the trial figures (DailyMed, Propecia label). Each roughly doubles the placebo rate while staying under 2%, and the label notes that resolution occurred in men who stopped and in most of those who continued. Postmarketing experience is where the harder claim lives: the label records reports of sexual dysfunction continuing after discontinuation, including erectile, libido, ejaculation and orgasm disorders, in the same category of spontaneous reporting as the FDA's 32 topical cases.

Set the two side by side and the honest position becomes visible. Oral finasteride's measured sexual side effect rates are low single digits above placebo. Topical delivers around three fifths of the systemic DHT suppression. If side effects track DHT suppression, which is the assumption the whole topical rationale rests on, then the expected topical rate is lower than oral's and above zero. Anyone promising zero is not reading their own product's trial.

Anyone weighing this against a stronger DHT blocker should note the trade runs the other way with dutasteride, which suppresses DHT further still. We compare the two in dutasteride vs finasteride.

Compounded means the formula is not standardised

In the US, the concentration in your bottle is not set by a regulator, and different pharmacies dispense different things. Compounded topical finasteride appears at 0.1%, 0.25% and 0.3%, sometimes alone and often combined with minoxidil at 5%, 6% or 8% in a single vehicle.

The trials that support the drug used a specific 0.25% spray with a defined applicator and dosing of 1 to 4 sprays a day. A 0.3% finasteride and 6% minoxidil combination bought online is a different product, and its evidence is inherited by analogy rather than earned by testing. The FDA's position is that compounded drugs are not FDA approved, meaning the agency has not evaluated their safety, effectiveness or quality.

Combination products carry both drugs' side effect profiles at once, which is easy to lose track of when they arrive in one bottle with one set of instructions. Minoxidil brings the first-months shed, scalp irritation and unwanted facial or body hair, and the vehicle matters for the irritation part, which we cover in minoxidil foam vs solution. Finasteride brings the DHT-related effects above.

A scalp reaction on a combination product could be either drug, and the only way to find out is to separate them. That is harder than it sounds when both arrive premixed, and it is one reason some dermatologists prefer to start the two separately even when the combination is cheaper. The same logic applies in the other direction to oral minoxidil, which moves the minoxidil half of the regimen off the scalp entirely and changes its side effect profile rather than removing it.

The risk that lands on somebody else

The transfer risk is the part of the FDA alert with the least coverage and the clearest mechanism. Approved finasteride tablets are film-coated specifically so that handling them does not expose anyone to the drug, and women are warned not to handle crushed or broken tablets because finasteride can cause abnormalities of the male fetus in a pregnant woman.

A liquid sprayed onto a scalp has no coating. The FDA notes that compounded topical finasteride carries a greater potential for inadvertent exposure to others, specifically women, through transfer of the applied product. Wet hair on a shared pillow, a hand run through the hair, a child picked up after application: none of these are exotic scenarios.

Finasteride is prescription-only in most countries and is not licensed for women of childbearing potential in any form. That restriction does not disappear because the product is a spray, and for a household where someone is pregnant or trying to conceive, it is the risk that deserves the most attention.

What to ask before starting

Whether any DHT blocker is worth considering depends first on what pattern you have and how far it has gone. The Norwood stage finder places it in a couple of minutes, and the receding hairline self-check separates a maturing hairline from a receding one, which is the distinction that decides whether treatment is on the table at all.

Questions worth putting to a dermatologist:

• What concentration and vehicle is being dispensed, and is it finasteride alone or combined with minoxidil?
• What is the expected effect on my serum DHT, and will it be measured before and during treatment?
• Which side effects should make me stop, and what is the plan if they persist after stopping?
• Is anyone in my household pregnant or trying to conceive, and what handling precautions follow?
• Is there a reason not to use the approved oral product, given that its risks are quantified and this one's are not?

That last question is the uncomfortable one. Oral finasteride has a regulator-reviewed label, thirty years of use and side effect rates measured against placebo in a controlled trial. Compounded topical finasteride has better local pharmacology, a good 24-week efficacy trial and no comparable safety accounting. Which of those trades you prefer is a genuine clinical judgement rather than an obvious answer.

Men who find neither acceptable and start weighing surgery should know that the two decisions are not alternatives. Transplanted hair is taken from a donor area that DHT does not attack, so it stays, but the native hair around it keeps thinning on its own schedule, which is why surgeons ask about medication before operating on younger patients. Reading what the before and after photos do and do not show comes first, and the arithmetic of paying for it is in hair transplant financing.

Nothing here is medical advice for any individual. Topical finasteride is a prescription decision in every country where it is legally available, the US supply is unapproved and unstandardised, and a dermatologist or hair restoration surgeon is the person to work out whether the version being offered to you resembles the one that was tested.

Frequently Asked Questions

Is topical finasteride FDA approved?

No. The FDA states there is no approved topical formulation of finasteride, and that compounded topical finasteride products do not have FDA-approved labeling, meaning the agency has not evaluated their safety, effectiveness or quality. The two approved finasteride products in the US are both oral tablets. A licensed 0.25% spray is approved in several European markets, including Italy, Germany, Luxembourg and Portugal.

Does topical finasteride cause sexual side effects?

It can. Its phase 3 trial found no meaningful difference in adverse events against placebo over 24 weeks, but the same trial measured a 34.5% drop in serum DHT, and the FDA has received reports of erectile dysfunction, decreased libido, brain fog, depression and suicidal ideation following use of compounded topical finasteride. Most of those reports state the effects persisted after the product was stopped. No study has produced a reliable incidence rate.

Is topical finasteride as effective as the oral tablet?

On the 24-week measure the two were numerically similar: roughly 20 additional hairs in the target area for topical against 21 for oral 1 mg, in a trial designed to compare them. The comparison has not been extended past 24 weeks, so nothing is known about how the two track over the years that treatment actually lasts.

Can topical finasteride be used with minoxidil?

The two are frequently compounded into a single product, and combining a DHT blocker with minoxidil is a standard approach because they work through unrelated mechanisms. The combination carries both side effect profiles at once, and a single bottle makes it impossible to tell which drug caused a reaction without separating them.